SILK
Silk Road Medical, Inc. Common StockSILK
SILK
Delisted
SILK was delisted on the 16th of September, 2024.
About: Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy. The company generates all of its revenue in the United States.
Employees: 474
Financial journalist opinion
Neutral
PRNewsWire
7 months ago
Boston Scientific Announces Results for Third Quarter 2024
MARLBOROUGH, Mass. , Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period.
Neutral
PRNewsWire
8 months ago
Boston Scientific Closes Acquisition of Silk Road Medical, Inc.
MARLBOROUGH, Mass. , Sept. 17, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that pioneered a new approach for stroke prevention and the treatment of carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR).
Neutral
Accesswire
9 months ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BALY and SILK on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Bally's Corporation (NYSE:BALY)'s sale to Standard General L.P. for $18.25 per share.
Neutral
GlobeNewsWire
9 months ago
SILK INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Merger and Looming Vote on September 5, 2024, of Silk Road Medical, Inc.
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Silk Road Medical, Inc. ( N asdaq : SILK ) , relating to its proposed merger with Boston Scientific Corporation and Seminole Merger Sub. Under the terms of the agreement, Silk Road stockholders will receive $27.50 in cash for each share they own.
Neutral
PRNewsWire
9 months ago
SILK INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Merger and Looming Vote on September 5, 2024, of Silk Road Medical, Inc.
NEW YORK , Aug. 20, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Silk Road Medical, Inc. (Nasdaq: SILK ), relating to its proposed merger with Boston Scientific Corporation and Seminole Merger Sub.
Neutral
Business Wire
9 months ago
SILK ROAD MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Silk Road Medical, Inc. - SILK
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Silk Road Medical, Inc. (NasdaqGS: SILK) to Boston Scientific Corporation (NYSE: BSX). Under the terms of the proposed transaction, shareholders of Silk Road will receive $27.50 in cash for each share of Silk Road that they own. KSF is seeking to determine whether this consideration and the process that led to.
Neutral
GlobeNewsWire
9 months ago
SILK Alert: Monsey Firm of Wohl & Fruchter Renews Investigation of the Proposed Sale of Silk Road Medical to Boston Scientific
MONSEY, N.Y., Aug. 19, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP has renewed its investigation into the fairness of the proposed sale of Silk Road Medical, Inc. (Nasdaq: SILK) (“SILK”) to Boston Scientific Corporation for $27.50 per share in cash.
Negative
Zacks Investment Research
9 months ago
Silk Road Medical (SILK) Reports Q2 Loss, Tops Revenue Estimates
Silk Road Medical (SILK) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.35 per share a year ago.
Neutral
GlobeNewsWire
10 months ago
Silk Road Medical Celebrates Milestone of 100,000 Transcarotid Artery Revascularization (TCAR) Procedures
Studied across thousands of patients and supported by hundreds of clinical publications, the TCAR pioneer has continually delivered positive outcomes through minimally invasive techniques
Neutral
PRNewsWire
10 months ago
SILK INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Merger of Silk Road Medical, Inc.
NEW YORK , July 29, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Silk Road Medical, Inc. (Nasdaq: SILK ), relating to its proposed merger with Boston Scientific Corporation and Seminole Merger Sub.
Charts implemented using Lightweight Charts™